Mode
Text Size
Log in / Sign up

Prostate adenocarcinoma

Part of Cancer

0 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Prostate adenocarcinoma

42 trials tracked for Prostate adenocarcinoma: 8 in phase 3 or 4 and 5 with published results. The most-cited published study has 301 citations.

42Trials tracked
8Phase 3 & 4
0Recruiting
5With published results
Phase distribution
Phase 4 1 Phase 3 7 Phase 2 20 Phase 1 3 Other / NA 11
  1. Phase 3 Clinical Trials of Adjuvant Androgen Deprivation in Localized Prostate Cancer Completed · 301 cited
  2. Phase 3 68Ga-RM2 PET/MRI in Biochemically Recurrent Prostate Cancer Completed · 67 cited
  3. Phase 3 68Ga-PSMA PET/CT in Detecting Prostate Cancer Recurrence in Patients With Elevated PSA After Initial Treatment Completed · 67 cited
  4. Phase 3 Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer Completed · 40 cited
  5. Phase 3 Study of 18F-DCFPyL PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer Completed
  6. Phase 4 Self-Administered Nitrous Oxide (SANO) During Transrectal Prostate Biopsy to Reduce Patient Anxiety and Pain Completed
Show 36 more trials
  1. Phase 3 Staging Prostate Cancer With Hybrid C11-Choline PET/MR and mpMRI Completed
  2. Phase 3 68Ga-PSMA-11 PET in Patients With Prostate Cancer Completed
  3. Phase 2 Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring Completed
  4. Phase 2 Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients Completed
  5. Phase 2 A Trial of Niraparib in Platinum-Sensitive Castration-Resistant Prostate Cancer With DNA Repair Defects Completed
  6. Phase 2 Cholecalciferol and Genistein Before Surgery in Treating Patients With Early Stage Prostate Cancer Completed
  7. Phase 2 Cabazitaxel With or Without Carboplatin in Treating Patients With Previously Treated Metastatic Castration-Resistant Prostate Cancer Completed
  8. Phase 2 Pentoxifylline, Atorvastatin, and Vitamin E in Treating Patients With Erectile Dysfunction After Radiation Therapy for Prostate Cancer Completed
  9. Phase 2 Hypofractionated Radiation Therapy for Treating Prostate Cancer High-Risk Features Following Radical Prostatectomy Completed
  10. Phase 2 Itraconazole in Treating Patients With Biochemically Relapsed Prostate Cancer Completed
  11. Phase 2 Apalutamide and Gonadotropin-Releasing Hormone Analog With or Without Abiraterone Acetate in Treating Participants With Prostate Cancer Completed
  12. Phase 2 Vaccine Therapy and Pembrolizumab in Treating Patients With Hormone-Resistant, Metastatic Prostate Cancer Completed
  13. Phase 2 Testosterone and Olaparib in Treating Patients With Castration-Resistant Prostate Cancer Completed
  14. Phase 2 Androgen Deprivation Therapy and Vorinostat Followed by Radical Prostatectomy in Treating Patients With Localized Prostate Cancer Completed
  15. Phase 2 Enzalutamide/Leuprolide +/- Abiraterone/Pred in Prostate Completed
  16. Phase 2 Tivantinib in Treating Patients With Metastatic Prostate Cancer Completed
  17. Phase 2 Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer Completed
  18. Phase 2 Gallium-68 PSMA-11 PET in Patients With Biochemical Recurrence Completed
  19. Phase 2 Bicalutamide and Goserelin or Leuprolide Acetate With or Without Cixutumumab in Treating Patients With Newly Diagnosed Metastatic Prostate Cancer Completed
  20. Phase 2 Hormone Therapy and Ipilimumab in Treating Patients With Advanced Prostate Cancer Completed
  21. Phase 2 Gallium Ga 68 DOTA-NeoBOMB1 and Gallium Ga 68 PSMA-R2 PET/MRI in Diagnosing Participants With Recurrent Prostate Cancer Completed
  22. Phase 2 Durvalumab and Tremelimumab in Treating Chemotherapy Naive Patients With Metastatic Castration-Resistant Prostate Cancer Completed
  23. Phase 1 Cabozantinib (XL184) in Men With Castrate-Resistant Prostate Cancer Completed
  24. Phase 1 Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer Completed
  25. Phase 1 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer Completed
  26. N/A Diet and Physical Activity Intervention for the Prevention of ADT-Induced Metabolic Changes in Patients With Prostate Cancer, TRIPLE-A PILOT Study Completed
  27. N/A Comparative Health Research Outcomes of NOvel Surgery in Prostate Cancer Completed
  28. N/A Pilot Trial Evaluating Stereotactic Body Radiotherapy With Integrated Boost for Clinically Localized Prostate Cancer (RAD 1203) Completed
  29. N/A Hypofractionated Image-Guided Radiotherapy For Prostate Cancer: The HEIGHT Trial Completed
  30. N/A Fluciclovine-PET/CT for Bone Metastases From Prostate Adenocarcinoma Completed
  31. N/A CyberKnife® as Monotherapy or Boost SBRT for Intermediate or High Risk Localized Prostate Cancer Completed
  32. N/A Degarelix Acetate Before and During Radiation Therapy in Treating Patients With Prostate Cancer Completed
  33. N/A PROState Pathway Embedded Comparative Trial Completed
  34. N/A Cholecalciferol Supplement in Treating Patients With Localized Prostate Cancer Undergoing Observation Completed
  35. N/A MRI-Guided Lattice Extreme Ablative Dose Radiotherapy For Prostate Cancer Completed
  36. N/A Increasing the Dose of Survivorship Care Planning in Improving Care and Outcomes in Prostate Cancer Survivors Receiving Androgen Deprivation Therapy Completed

Showing the 42 most-cited and recently-updated of 42 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found Updated — new results For clinicians

Prostate adenocarcinoma: what the trials found

Short-term androgen deprivation has been shown to significantly improve clinical outcomes in prostate adenocarcinoma, with a 90% vs 81% rate of biochemical disease-free survival at 5 years (p=0.01), an 83% vs 94% metastasis-free survival rate (p=0.01), and an 86% vs 95% overall survival rate at 5 years (p=0.009) 5.

Imaging modalities including 68Ga-RM2 6, 68Ga-PSMA-11 7, Ga-PSMA-11 9, C-11 choline PET tracer 11, and 18F-DCFPyL have been evaluated in clinical trials. Notably, 131 participants had their intended treatment plans changed based on 18F-DCFPyL PET/CT imaging results 10.

Self-administered nitrous oxide was evaluated in a Phase 4 trial 4. Additionally, hypofractionated radiation therapy did not show statistically significant differences in the urinary or bowel domains of the Expanded Prostate Cancer Index (EPIC) at two years 8.

Recent results — preliminary, needs further review

  • Niraparib Pill showed a 6-month radiographic progression-free survival (rPFS6) of 6 (p=0.006), a PSA50 response in 3 patients (p=0.05), and a time to PSA progression of 11.2 (p=0.05) 2.
  • Androgen Suppression was evaluated in a Phase 2 trial 1.
  • Gonadotrophin Releasing Hormone was evaluated in a Phase 2 trial 12.

For the clinician treating this condition

  • Short-term androgen deprivation is associated with significant improvements in biochemical disease-free survival, metastasis-free survival, and overall survival at the 5-year mark.
  • Multiple PET tracers (68Ga-RM2, 68Ga-PSMA-11, Ga-PSMA-11, C-11 choline, and 18F-DCFPyL) have been established in clinical trials for imaging purposes.
  • Hypofractionated radiation therapy did not result in statistically significant changes to urinary or bowel EPIC scores at the two-year follow-up.

AI synthesis of 11 cited trials, updated Jun 25, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
No published articles yet for this condition. Check back soon.

Research across Cancer

Related studies from across the Cancer family.

AI diagnostic tools show high accuracy but limited real-world validation in systematic review
Oncology Meta-analysis
AI diagnostic tools show high accuracy but limited real-world validation in systematic review Artificial intelligence shows high accuracy in detecting various medical conditions
This systematic review of 24 studies synthesizes evidence on AI and deep learning for disease detection across multiple imaging modalities. …
New analysis of 24 studies shows AI tools can reach over 90% accuracy in spotting everything from lung cancer to skin disorders.
Metabolic reprogramming of lipid-associated macrophages creates an immunosuppressive microenvironment in pancreatic ductal adenocarcinoma
Allergy & Immunology Sys. Review
Metabolic reprogramming of lipid-associated macrophages creates an immunosuppressive microenvironment in pancreatic ductal adenocarcinoma Specific immune cells help pancreatic cancer grow and spread
This narrative review characterizes the role of lipid-associated macrophages (LAMs) and their metabolic pathways in the pancreatic ductal ad…
Researchers identified how specific fat-loving immune cells create a shield that protects pancreatic tumors from the body's natural defenses…
Hypofractionated and dose-boosted radiotherapy improves metastasis-free survival in clinically localised prostate cancer
Urology Meta-analysis
Hypofractionated and dose-boosted radiotherapy improves metastasis-free survival in clinically localised prostate cancer Dose-boosting radiotherapy may improve survival for high-risk prostate cancer patients
This systematic review and meta-analysis evaluated hypofractionated and dose-boosted radiotherapy fractionation schedules versus standard ra…
Combining external beam radiotherapy with brachytherapy or a focal boost significantly improved metastasis-free survival in patients with cl…
Darolutamide plus ADT and docetaxel reduces death risk 37% in metastatic hormone-sensitive prostate cancer
Drug Pipeline RCT
Darolutamide plus ADT and docetaxel reduces death risk 37% in metastatic hormone-sensitive prostate cancer New drug treatment lowers death risk for advanced prostate cancer patients by thirty seven percent
This phase 3 randomized controlled trial enrolled 472 European patients with metastatic hormone-sensitive prostate cancer. Darolutamide 600 …
A large study found that adding darolutamide to standard care helped European patients live longer and delayed cancer growth. Serious side e…
Intensity-modulated radiotherapy reduces acute and delayed G2+GI toxicities versus 3D-CRT in high-risk prostate cancer
Urology RCT
Intensity-modulated radiotherapy reduces acute and delayed G2+GI toxicities versus 3D-CRT in high-risk prostate cancer Post hoc analysis shows IMRT reduces radiation side effects for high-risk prostate cancer
This post hoc analysis of a Phase III randomized controlled trial evaluated intensity-modulated radiotherapy (IMRT) versus three-dimensional…
A post hoc analysis of a Phase III trial found that intensity-modulated radiotherapy reduced radiation side effects compared to older techni…
Nanomedicine strategies show promise for targeting pancreatic ductal adenocarcinoma
Infectious Disease Sys. Review
Nanomedicine strategies show promise for targeting pancreatic ductal adenocarcinoma Nanomedicine options for pancreatic cancer remain theoretical in current reviews
This narrative review surveys nanomedicine approaches for pancreatic ductal adenocarcinoma, including polymeric nanoparticles, small-molecul…
Current reviews suggest nanomedicine and other advanced therapies for pancreatic cancer are still theoretical concepts without proven clinic…
Narrative review on KMT2C alterations in gastrointestinal cancers and therapeutic implications
Allergy & Immunology Sys. Review
Narrative review on KMT2C alterations in gastrointestinal cancers and therapeutic implications Genetic changes in gut cancers may open new treatment doors for patients
This narrative review synthesizes evidence on KMT2C alterations across gastrointestinal malignancies. It links KMT2C dysfunction to transcri…
A review of genetic changes in gastrointestinal cancers suggests new ways to treat tumors by targeting specific DNA repair weaknesses.
Guideline-based case report: neoadjuvant alectinib in ALK-rearranged stage IIIB lung cancer
Drug Pipeline Guideline
Guideline-based case report: neoadjuvant alectinib in ALK-rearranged stage IIIB lung cancer One woman shows how alectinib shrinks lung cancer before surgery
This guideline-based case report describes a 57-year-old woman with ALK-rearranged stage IIIB lung cancer treated with neoadjuvant alectinib…
A single case shows alectinib shrinking lung cancer before surgery. This report offers hope for specific patients but needs more study.
Systematic review and meta-analysis shows darolutamide combination therapy improves survival in advanced prostate cancer
Drug Pipeline Meta-analysis
Systematic review and meta-analysis shows darolutamide combination therapy improves survival in advanced prostate cancer Darolutamide plus ADT improves survival in advanced prostate cancer patients
This systematic review and meta-analysis of randomized controlled trials evaluated darolutamide combination therapy versus placebo plus ADT …
A large analysis of trials shows darolutamide combined with standard treatment extends life and delays cancer spread in advanced prostate ca…
Case report and literature review on IgG4-related disease misdiagnosed as pancreatic cancer in a 70-year-old male
Rheumatology Meta-analysis
Case report and literature review on IgG4-related disease misdiagnosed as pancreatic cancer in a 70-year-old male A 70-year-old man avoided unnecessary surgery after doctors found a treatable autoimmune condition
This case report and literature review examines a 70-year-old male patient with IgG4-related autoimmune pancreatitis initially suspected as …
A 70-year-old man with a pancreatic mass was found to have a treatable autoimmune disease, sparing him from unnecessary surgery.
Robot-assisted distal pancreatectomy reduces blood loss and conversions but increases operative time and cost
Oncology Meta-analysis
Robot-assisted distal pancreatectomy reduces blood loss and conversions but increases operative time and cost Robot Surgery Matches Laparoscopic for Pancreas Cancer Outcomes
This systematic review and meta-analysis of 15790 patients undergoing distal pancreatectomy found that robot-assisted distal pancreatectomy …
New data shows robot-assisted pancreas surgery matches standard laparoscopic methods in safety and cancer control, while cutting blood loss …
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma
Oncology FDA Approval
FDA approves OPDIVO QVANTIG for multiple advanced cancer indications including renal cell carcinoma and melanoma FDA approves subcutaneous nivolumab combination for multiple advanced cancers
This FDA approval document grants authorization for OPDIVO QVANTIG, a subcutaneous combination of nivolumab and hyaluronidase, for specified…
The FDA has approved a new subcutaneous form of nivolumab for several advanced cancers, offering a more convenient treatment option for elig…